Difference between revisions of "Traebert M, et al, Eur J Pharmacol (2004), cited as Ref 35 in DOI: 10.1007/s11886-020-01293-2 (Q11029)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Sixth Author string (P154): Suter W, #quickstatements; #temporary_batch_1592835855539)
(‎Created claim: Page(s) (P105): 41-48, #quickstatements; #temporary_batch_1592836326594)
 
(4 intermediate revisions by the same user not shown)
Property / Published In Name String
 +
Eur J Pharmacol
Property / Published In Name String: Eur J Pharmacol / rank
 +
Normal rank
Property / DOI Identifier
 +
Property / DOI Identifier: 10.1016/j.ejphar.2003.11.003 / rank
 +
Normal rank
Property / PubMed ID
 +
Property / PubMed ID: 14729380 / rank
 +
Normal rank
Property / Volume
 +
484
Property / Volume: 484 / rank
 +
Normal rank
Property / Page(s)
 +
41-48
Property / Page(s): 41-48 / rank
 +
Normal rank

Latest revision as of 14:33, 22 June 2020

Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.
Language Label Description Also known as
English
Traebert M, et al, Eur J Pharmacol (2004), cited as Ref 35 in DOI: 10.1007/s11886-020-01293-2
Cited in: "Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty" Curr Cardiol Rep; 2020 04 29 ; 22 (5) 34.

    Statements

    Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells (English)
    0 references
    2004
    0 references
    Traebert M
    0 references
    Dumotier B
    0 references
    Meister L
    0 references
    Hoffmann P
    0 references
    Dominguez-Estevez M
    0 references
    Suter W
    0 references
    Eur J Pharmacol
    0 references
    0 references
    484
    0 references
    41-48
    0 references